Compare HTD & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTD | CERT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.3M | 860.9M |
| IPO Year | 2003 | 2020 |
| Metric | HTD | CERT |
|---|---|---|
| Price | $25.82 | $6.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 51.5K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $22.38 | $5.19 |
| 52 Week High | $26.21 | $13.88 |
| Indicator | HTD | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 55.41 |
| Support Level | $24.34 | $5.93 |
| Resistance Level | $26.16 | $6.48 |
| Average True Range (ATR) | 0.43 | 0.28 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 74.42 | 76.87 |
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.